Please use this identifier to cite or link to this item: https://hdl.handle.net/10356/85385
Full metadata record
DC FieldValueLanguage
dc.contributor.authorChalmers, James D.en
dc.contributor.authorChotirmall, Sanjay Hareshen
dc.date.accessioned2019-07-09T08:55:20Zen
dc.date.accessioned2019-12-06T16:02:51Z-
dc.date.available2019-07-09T08:55:20Zen
dc.date.available2019-12-06T16:02:51Z-
dc.date.issued2018en
dc.identifier.citationChotirmall, S. H., & Chalmers, J. D. (2018). RESPIRE : breathing new life into bronchiectasis. European Respiratory Journal, 51(1), 1702444-. doi:10.1183/13993003.02444-2017en
dc.identifier.issn0903-1936en
dc.identifier.urihttps://hdl.handle.net/10356/85385-
dc.identifier.urihttp://hdl.handle.net/10220/49222en
dc.description.abstractRESPIRE, definable as “the recovery of hope, courage and strength after a time of difficulty”, is apt in the context of bronchiectasis therapy. Despite its recent renaissance, including the publication of the first international guidelines for the management of bronchiectasis, only a single treatment recommendation in the 2017 European Respiratory Society guidelines was supported by high-quality evidence [1]. This is a timely reminder of the real and challenging battle ahead, to deliver evidence-based appropriate and effective therapies to patients. In this issue of the European Respiratory Journal, a major “blow” in this battle has been struck and appears to have landed its intended target [2, 3]. The RESPIRE 1 and 2 trials evaluated 32.5 mg ciprofloxacin dry powder inhalation (DPI) administered twice daily versus placebo in two separate 2×2 arm trials. Taken together, these two trials represent the largest clinical trial programme ever conducted in bronchiectasis. Each trial studied a 14- and 28-day on/off drug regime over a 48-week period. The two trials differed by: 1) their enrolling countries; and 2) statistical handling of the data. RESPIRE 1 largely enrolled across Europe, North and South America, Australia and included Japan, while RESPIRE 2 focused on Asia and Eastern Europe. The inclusion criteria were the same for each set of trials, requiring patients with bronchiectasis infected with one of a list of the most commonly identified pathogens, and a history of ≥2 exacerbations in the previous year.en
dc.language.isoenen
dc.relation.ispartofseriesEuropean Respiratory Journalen
dc.rights© 2018 ERS. All rights reserved.en
dc.subjectScience::Medicineen
dc.subjectBronchiectasisen
dc.subjectBreathingen
dc.titleRESPIRE : breathing new life into bronchiectasisen
dc.typeJournal Articleen
dc.contributor.schoolLee Kong Chian School of Medicine (LKCMedicine)en
dc.identifier.doi10.1183/13993003.02444-2017en
item.fulltextNo Fulltext-
item.grantfulltextnone-
Appears in Collections:LKCMedicine Journal Articles

Google ScholarTM

Check

Altmetric

Items in DR-NTU are protected by copyright, with all rights reserved, unless otherwise indicated.